TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11699053

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (1,142.0 +/- 79.64 microg/d for at least 12 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no corticosteroids for at least 1 year)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 9159976

Group type: EXPERIMENTAL
Intervention: Behavioural hearing tactics
Number of subjects: 19

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 19
Study: 7960188

Group type: EXPERIMENTAL
Intervention: Surgical procedures applicable to 14 patients with complete spermatogenesis and distal obstruction of the excurrent ducts.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 102
Study: 30315901

Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5, 1.25, or 5 mg/day)
Number of subjects: 27528

Group type: COMPARATOR
Intervention: Placebo or intramuscular interferon beta‐1a (IFNβ‐1a IM)
Number of subjects: 27528
Study: 27928888

Group type: EXPERIMENTAL
Intervention: Self-care tools plus limited telephone support
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed intervention/usual care
Number of subjects: 80
Study: 26154700

Group type: EXPERIMENTAL
Intervention: Long-acting local anesthetic (bupivacaine hydrochloride, 0.50%)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 99
Study: 23257173

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21318442

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 42
Study: 18496062

Group type: EXPERIMENTAL
Intervention: Heparin flushes (1:100 dilution)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Splints
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Younger age, wrist and scalp insertions, and 24-gauge catheters
Number of subjects: 88
Study: 16517117

Group type: EXPERIMENTAL
Intervention: Dean‐Woodcock Sensory‐Motor Battery (DWSMB)
Number of subjects: 500
Study: 12706129

Group type: EXPERIMENTAL
Intervention: Enteral nutrition enriched with glutamine (0.7 g kg(‐1)day(‐1))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isonitrogenous control
Number of subjects: 25
Study: 10910450

Group type: EXPERIMENTAL
Intervention: Continued MMF treatment (2 g b.i.d.) in group A, n=22
Number of subjects: 48

Group type: COMPARATOR
Intervention: Switching to AZA treatment (1 mg/kg) in group B, n=26
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 48
Study: 8731618

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patches
Number of subjects: 1686
Study: 1569341

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice a day for 3 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Chloroquine (standard course)
Number of subjects: 38
Study: 2866073

Group type: EXPERIMENTAL
Intervention: MK-208 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MK-208 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MK-208 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31478796

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Usual-advice
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no advice)
Number of subjects: 84
Study: 28952607

Group type: EXPERIMENTAL
Intervention: 180 mcg/day of vitamin K2 (menaquinone-7, MK-7)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 27456837

Group type: EXPERIMENTAL
Intervention: Couples calls (CC)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Individual calls (IC)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Diabetes education (DE)
Number of subjects: 280
Study: 25379541

Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine + fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine + fentanyl
Number of subjects: 50
Study: 22487663

Group type: EXPERIMENTAL
Intervention: Triple therapy (morphine, ketorolac, and butylscopolammonium bromide)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Double therapy (morphine and ketorolac)
Number of subjects: 89
Study: 20190331

Group type: EXPERIMENTAL
Intervention: Conversion from predominantly central sleep apnoea (CSA) to predominantly obstructive sleep apnoea (OSA)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nonconversion group (remained predominantly CSA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Conversion from CSA to OSA
Number of subjects: 98
Study: 16519928

Group type: EXPERIMENTAL
Intervention: Light conducting inserts
Number of subjects: 60

Group type: COMPARATOR
Intervention: Positive control group (incremental technique)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inactive inserts
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative control group (single increment)
Number of subjects: 60
Study: 16324616

Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 124

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 124
Study: 12216965

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 445

Group type: COMPARATOR
Intervention: Ibuprofen 2,400 mg/day
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 445
Study: 9470014

Group type: EXPERIMENTAL
Intervention: Prick skin tests using a battery of food antigens
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Screening prick skin tests for seven foods (milk, egg, peanut, soy, wheat, cod/catfish, cashew)
Number of subjects: 165
Study: 7648766

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg (S)-ketamine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg (S)-ketamine
Number of subjects: 5

Group type: COMPARATOR
Intervention: 0 mg/kg (S)-ketamine (control)
Number of subjects: 5
Study: 2608196

Group type: EXPERIMENTAL
Intervention: Chorionic gonadotropin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovariostatics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovulation inducers
Number of subjects: 0
Study: 1009523

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (1000 mg/m2 every 3 weeks) iv
Number of subjects: 443

Group type: COMPARATOR
Intervention: Cyclophosphamide (700 mg/m2 every 3 weeks) iv plus CCNU (70 mg/m2 every 6 weeks) orally
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Combination regimen
Number of subjects: 443

Group type: COMPARATOR
Intervention: Single agent (Cyclophosphamide)
Number of subjects: 443
Study: 31983658

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 31271068

Group type: EXPERIMENTAL
Intervention: Edaravone (MCI-186)
Number of subjects: 67
Study: 27787467

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise (10 × 1 minute at 100% of maximal treadmill velocity with 1 minute recovery)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise
Number of subjects: 21
Study: 25835516

Group type: EXPERIMENTAL
Intervention: Experience Corps intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study: 24219758

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (PICO) for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Educational attention (control group)
Number of subjects: 50
Study: 21357641

Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 64
Study: 19291601

Group type: EXPERIMENTAL
Intervention: 64-slice CT with 80 cc CM at 5 cc/sec followed by a 50 cc saline chaser bolus containing 20% contrast media
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dual source CT with a CM protocol adapted for scan time and identical saline/CM chaser bolus
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both 64-slice and dual source CT using a 20% saline chaser bolus
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CM protocol adapted for scan time
Number of subjects: 97
Study: 17290009

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 31

Group type: COMPARATOR
Intervention: L-NMMA (low dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: L-NMMA (high dose)
Number of subjects: 31
Study: 15344451

Group type: EXPERIMENTAL
Intervention: Feature selection method for shape-based classification
Number of subjects: 0
Study: 11129924

Group type: EXPERIMENTAL
Intervention: Individualised, behavioural approach to rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific nursing interventions
Number of subjects: 0
Study: 9105060

Group type: EXPERIMENTAL
Intervention: ONO‐1078 (pranlukast), 450 mg twice daily
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 1443452

Group type: EXPERIMENTAL
Intervention: Native Parietaria product
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modified Parietaria product
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treated groups (Native and Modified Parietaria)
Number of subjects: 24
Study: 3954918

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 0
Study: 29959285

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) training
Number of subjects: 31
Study: 28631682

Group type: EXPERIMENTAL
Intervention: Traditional therapy combined with homeovox
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional therapy alone
Number of subjects: 40
Study: 26508659

Group type: EXPERIMENTAL
Intervention: Adenosine treatment for 6 months
Number of subjects: 38
Study: 24594076

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50-100mg daily for 2 days
Number of subjects: 6
Study: 21945457

Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 21
Study: 19388861

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison between acupuncture and sham treatment
Number of subjects: 24
Study: 18091190

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable
Number of subjects: 323
Study: 15126928

Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily, hydrochlorothiazide 12.5-25 mg daily)
Number of subjects: 4695

Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (placebo)
Number of subjects: 4695

Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment
Number of subjects: 4695

Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment in diabetic patients (n=492)
Number of subjects: 4695
Study: 11200354

Group type: EXPERIMENTAL
Intervention: Classification of complications from interventional procedures
Number of subjects: 193
Study: 10211918

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amitriptyline 75 mg/day
Number of subjects: 42
Study: 8582387

Group type: EXPERIMENTAL
Intervention: Programmed ventricular stimulation from the right ventricular apex
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Programmed ventricular stimulation from the outflow tract
Number of subjects: 66

Group type: COMPARATOR
Intervention: Programmed ventricular stimulation (general)
Number of subjects: 66
Study: 2197535

Group type: EXPERIMENTAL
Intervention: 8 g/d cotrimoxazole (TMP/SMX) i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: 600 mg aerosolized pentamidine
Number of subjects: 60
Study: 347887

Group type: EXPERIMENTAL
Intervention: L-tryptophan (6 g daily) and ECT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and ECT
Number of subjects: 0
Study: 30124597

Group type: EXPERIMENTAL
Intervention: Endotoxin (1 ng/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Septic shock patients
Number of subjects: 0
Study: 26420886

Group type: EXPERIMENTAL
Intervention: IVIG (0.4 g/kg 10% IVIG every 2 weeks for a total of 5 infusions, 2 g/kg total dose)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 50
Study: 25529292

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urban residence and history of TB contact/disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG vaccine strain, LTBI, HIV infection, asymptomatic malaria, growth z-scores, childhood anthelminthic treatment, maternal BCG scar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokine responses at one year
Number of subjects: 0
Study: 23484892

Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1 INH‐nf; human)
Number of subjects: 16
Study: 21073372

Group type: EXPERIMENTAL
Intervention: Irsogladine 4 mg/day
Number of subjects: 119

Group type: COMPARATOR
Intervention: Famotidine 40 mg/day
Number of subjects: 119
Study: 19584759

Group type: EXPERIMENTAL
Intervention: Option 1 (EQ-5D)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Option 2 (EQ-5D)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Option 3 (EQ-5D)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Option 3 (SF-6D)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Option 2 (SF-6D)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Option 1 (SF-6D)
Number of subjects: 389
Study: 16758938

Group type: EXPERIMENTAL
Intervention: 20% Albumin (Plasbumin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 4% Succinylated gelatin (helofusin)
Number of subjects: 36
Study: 15116294

Group type: EXPERIMENTAL
Intervention: Levofloxacin administered as an infusion of 500 mg/h for 1.5 h (total dose, 750 mg) with additional drugs for specific pathogens (ceftazidime or piperacillin/tazobactam for P. aeruginosa and vancomycin for methicillin-resistant S. aureus).
Number of subjects: 58
Study: 11501226

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9141217

Group type: EXPERIMENTAL
Intervention: Imule system (needleless jet-injector)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard syringe technique
Number of subjects: 0
Study: 8426211

Group type: EXPERIMENTAL
Intervention: Hepatic arterial therapy with floxuridine, mitomycin, and carmustine (FMB)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hepatic arterial therapy with floxuridine alone (F)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 95
Study: 6150140

Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin prepared by Cohn fractionation of pooled plasma
Number of subjects: 12
Study: 31264762

Group type: EXPERIMENTAL
Intervention: recombinant FVIII (rFVIII)
Number of subjects: 54

Group type: COMPARATOR
Intervention: plasma-derived FVIII (pdFVIII)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SIPPET study findings
Number of subjects: 54
Study: 29509293

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (gutta-percha)
Number of subjects: 6
Study: 26166213

Group type: EXPERIMENTAL
Intervention: Episode transmitting a prevention message
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Counterarguing
Number of subjects: 208
Study: 24577097

Group type: EXPERIMENTAL
Intervention: 100 mg/day of phosphatidylserine enriched with docosahexaenoic acid (PS-DHA)
Number of subjects: 122
Study: 22337277

Group type: EXPERIMENTAL
Intervention: Correction group (received infusion with fresh-frozen plasma and/or platelets)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No correction group (no transfusion)
Number of subjects: 72
Study: 20559006

Group type: EXPERIMENTAL
Intervention: Desloratadine (DL) 5 mg once daily
Number of subjects: 716

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 716
Study: 17991266

Group type: EXPERIMENTAL
Intervention: Single use LMA Flexible
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reusable LMA Flexible
Number of subjects: 100
Study: 16458655

Group type: EXPERIMENTAL
Intervention: Prenatal supplements with 30 mg of iron as ferrous sulfate (n = 218 women)
Number of subjects: 429

Group type: COMPARATOR
Intervention: 0 mg of iron (control group, n = 211 women)
Number of subjects: 429
Study: 15542241

Group type: EXPERIMENTAL
Intervention: Phobia-related words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phobia-unrelated words
Number of subjects: 0
Study: 11081593

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine
Number of subjects: 51
Study: 8889421

Group type: EXPERIMENTAL
Intervention: suxamethonium (1 mg kg‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: saline (0.02 mL kg‐1)
Number of subjects: 11
Study: 2005165

Group type: EXPERIMENTAL
Intervention: Cemented Thompson stem
Number of subjects: 53

Group type: COMPARATOR
Intervention: Uncemented Austin Moore stem
Number of subjects: 53
Study: 6435961

Group type: EXPERIMENTAL
Intervention: L-Lysine monohydrochloride 1,248 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: L-Lysine monohydrochloride 624 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: L-Lysine monohydrochloride (both dosages)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31009578

Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waiting-list control (6-month delay in treatment)
Number of subjects: 21
Study: 27179286

Group type: EXPERIMENTAL
Intervention: ¡Cocinar Para Su Salud! (Cook for Your Health!) dietary intervention
Number of subjects: 0
Study: 26117247

Group type: EXPERIMENTAL
Intervention: Integrated Treatment Adherence Program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enhanced Assessment and Monitoring
Number of subjects: 30
Study: 23623047

Group type: EXPERIMENTAL
Intervention: Olmesartan at 20 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Valsartan at 80 mg/day
Number of subjects: 100
Study: 20955210

Group type: EXPERIMENTAL
Intervention: Low-dose fenoldopam infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17
Study: 19164400

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (exercise training twice weekly for 12 weeks, nutritional and self-care advice, education about disease and energy conservation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 16676703

Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15526230

Group type: EXPERIMENTAL
Intervention: ALA fluorescence detection
Number of subjects: 115

Group type: COMPARATOR
Intervention: White light cystoscopy
Number of subjects: 115
Study: 11009285

Group type: EXPERIMENTAL
Intervention: Tissue harmonic imaging
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard echocardiographic assessment
Number of subjects: 40
Study: 9279337

Group type: EXPERIMENTAL
Intervention: Tamoxifen (extended duration by an additional five years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (standard duration)
Number of subjects: 0
Study: 8377777

Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen cream with SPF 17
Number of subjects: 588

Group type: COMPARATOR
Intervention: Base cream (control)
Number of subjects: 588
Study: 3535685

Group type: EXPERIMENTAL
Intervention: Bronchodilator (salbutamol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 27855541

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Behavioral Therapy (BT)
Number of subjects: 41
Study: 27357583

Group type: EXPERIMENTAL
Intervention: Bionator or Activator followed by fixed appliances
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated Class II malocclusion)
Number of subjects: 40
Study: 24722498

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2425
Study: 22712373

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 60
Study: 20420955

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study: 18400466

Group type: EXPERIMENTAL
Intervention: Observation condition (third party observer present)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control condition (no observer present)
Number of subjects: 70
Study: 16524126

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (Travatan)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (Xalatan)
Number of subjects: 27
Study: 11642644

Group type: EXPERIMENTAL
Intervention: Patient education and high‐intensity strength intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9647369

Group type: EXPERIMENTAL
Intervention: Abnormal duodenal mucosa (n = 26)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Scallops and grooves (n = 7)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Scallops alone (n = 4)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Grooves alone (n = 3)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Normal duodenum (n = 100)
Number of subjects: 126